Your browser doesn't support javascript.
loading
Treatment modalities in cancer-associated venous thromboembolism (VTE).
Soto Alsar, Javier; Gutiérrez Ortiz de la Tabla, Ana; Ortega Morán, Laura; Muñoz Martín, Andrés J.
Afiliación
  • Soto Alsar J; Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain.
  • Gutiérrez Ortiz de la Tabla A; Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain.
  • Ortega Morán L; Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain; Cancer & Thrombosis Section, Spanish Society of Medical Oncology (SEOM), Spain.
  • Muñoz Martín AJ; Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain; Cancer & Thrombosis Section, Spanish Society of Medical Oncology (SEOM), Spain. Electronic address: andresmunmar@hotmail.com.
Best Pract Res Clin Haematol ; 35(1): 101354, 2022 03.
Article en En | MEDLINE | ID: mdl-36030074
Anticoagulation is the cornerstone of cancer-associated VTE treatment, including vitamin K antagonists (VKA), unfractionated heparin (UFH), fondaparinux, low-molecular-weight heparins (LMWH) and direct oral anticoagulants (DOACs). The goals of anticoagulant therapy in cancer patients with cancer-associated thrombosis (CAT) are to improve symptoms, reduce risk of recurrent VTE or fatal pulmonary embolism (PE), and decrease the risk of post-thrombotic syndrome (PTS) and chronic thromboembolic pulmonary hypertension. Although LMWH have been the standard of care for a long time for VTE treatment in cancer patients, showing superiority over the classic VKA, in the recent years the landscape of anticoagulant therapy has significantly changed with the inclusion of DOACs in this population.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tromboembolia Venosa / Neoplasias Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Best Pract Res Clin Haematol Asunto de la revista: HEMATOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: España Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tromboembolia Venosa / Neoplasias Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Best Pract Res Clin Haematol Asunto de la revista: HEMATOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: España Pais de publicación: Países Bajos